4.6 Review

Clinical Management of Congenital Hypogonadotropic Hypogonadism

Journal

ENDOCRINE REVIEWS
Volume 40, Issue 2, Pages 669-710

Publisher

ENDOCRINE SOC
DOI: 10.1210/er.2018-00116

Keywords

-

Funding

  1. Programme Hospitalier de Recherche Clinique Hypo-Proteo
  2. Assistance Publique Hopitaux de Paris
  3. Ministry of Health
  4. Agence Francaise de Lutte contre le Dopage (the French antidoping agency)
  5. Fondation pour la Recherche Medicale Grant FRM-2009
  6. University Paris-Sud (Bonus Qualite Recherche)
  7. Agence Nationale de la Recherche Grant [ANR-09-GENO-017-01]
  8. Programme Hospitalier de Recherche Clinique, French Ministry of Health, Assistance Publique Hopitaux de Paris [P081216/IDRCB 2009-A00892-55]
  9. Foundation for Pediatric Research
  10. Academy of Finland
  11. Sigrid Juselius Foundation
  12. Research Funds of Helsinki Central Hospital
  13. Swiss National Science Foundation [SNF 31003A 153328]

Ask authors/readers for more resources

The initiation and maintenance of reproductive capacity in humans is dependent on pulsatile secretion of the hypothalamic hormone GnRH. Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder that results from the failure of the normal episodic GnRH secretion, leading to delayed puberty and infertility. CHH can be associated with an absent sense of smell, also termed Kallmann syndrome, or with other anomalies. CHH is characterized by rich genetic heterogeneity, with mutations in >30 genes identified to date acting either alone or in combination. CHH can be challenging to diagnose, particularly in early adolescence where the clinical picture mirrors that of constitutional delay of growth and puberty. Timely diagnosis and treatment will induce puberty, leading to improved sexual, bone, metabolic, and psychological health. In most cases, patients require lifelong treatment, yet a notable portion of male patients (approximate to 10% to 20%) exhibit a spontaneous recovery of their reproductive function. Finally, fertility can be induced with pulsatile GnRH treatment or gonadotropin regimens in most patients. In summary, this review is a comprehensive synthesis of the current literature available regarding the diagnosis, patient management, and genetic foundations of CHH relative to normal reproductive development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available